Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2025 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.750-0.800 for the period. The company issued revenue guidance of $3.0 billion-$3.1 billion.

Amneal Pharmaceuticals Stock Up 0.2%

Shares of AMRX stock opened at $12.98 on Tuesday. The firm has a 50 day moving average of $12.29 and a 200-day moving average of $10.35. Amneal Pharmaceuticals has a 52 week low of $6.68 and a 52 week high of $13.48. The company has a market cap of $4.08 billion, a price-to-earnings ratio of 649.32 and a beta of 1.34.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.The firm had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. Analysts anticipate that Amneal Pharmaceuticals will post 0.53 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AMRX. Barclays initiated coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $15.00 price target on the stock. Piper Sandler reissued an “overweight” rating and set a $13.00 target price (up previously from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Truist Financial set a $15.00 target price on shares of Amneal Pharmaceuticals in a report on Wednesday, January 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. upped their target price on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $13.80.

Insider Transactions at Amneal Pharmaceuticals

In other news, Director Ted C. Nark sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $11.72, for a total transaction of $586,000.00. Following the completion of the transaction, the director directly owned 291,029 shares of the company’s stock, valued at $3,410,859.88. This trade represents a 14.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Nikita Shah sold 131,856 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total value of $1,571,723.52. Following the completion of the sale, the executive vice president owned 146,403 shares of the company’s stock, valued at $1,745,123.76. This trade represents a 47.39% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 231,856 shares of company stock valued at $2,743,724. 17.45% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Rubric Capital Management LP boosted its stake in Amneal Pharmaceuticals by 5.3% during the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock valued at $123,473,000 after buying an additional 624,609 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Amneal Pharmaceuticals by 2.5% in the third quarter. Dimensional Fund Advisors LP now owns 5,431,134 shares of the company’s stock valued at $54,361,000 after purchasing an additional 133,764 shares in the last quarter. Nantahala Capital Management LLC raised its position in Amneal Pharmaceuticals by 14.7% during the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after buying an additional 558,877 shares during the period. Millennium Management LLC increased its holdings in shares of Amneal Pharmaceuticals by 32.6% in the 1st quarter. Millennium Management LLC now owns 2,087,398 shares of the company’s stock valued at $17,492,000 after purchasing an additional 512,842 shares during the period. Finally, Qube Research & Technologies Ltd grew its position in Amneal Pharmaceuticals by 8.2% during the second quarter. Qube Research & Technologies Ltd now owns 1,910,862 shares of the company’s stock valued at $15,459,000 after purchasing an additional 144,897 shares in the last quarter. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.